Get the Stockscreener App
9.35
1.89%
-0.18
Artelo Biosciences Inc stock is traded at $9.35, with a volume of 23,701.
It is down -1.89% in the last 24 hours and down -34.02% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$9.53
Open:
$9.455
24h Volume:
23,701
Relative Volume:
0.04
Market Cap:
$6.59M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-2.9589
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
-6.69%
1M Performance:
-34.02%
6M Performance:
+34.34%
1Y Performance:
+24.67%
1-Day Range:
$9.25
$9.66
1-Week Range:
$9.1623
$10.55
52-Week Range:
$4.9176
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
9.35 | 12.63M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences Ends Securities Purchase Agreement - TipRanks
Artelo Biosciences terminates securities purchase agreement - MarketScreener
Artelo Biosciences Inc. Rebounds From Oversold Zone — Now What2025 Big Picture & High Return Stock Watch Alerts - beatles.ru
Artelo Biosciences: Boral Capital Maintains Buy Rating, PT Raised to $18. - AInvest
Artelo Biosciences Q2 2025 Earnings Miss Market Expectations; Short-Term Optimism Tempered by Broader Sector Trends - AInvest
Is Artelo Biosciences Inc. being accumulated by smart money2025 Analyst Calls & Comprehensive Market Scan Insights - thegnnews.com
Artelo Biosciences Sees Bullish Trend with KDJ Golden Cross and Bullish Marubozu - AInvest
Artelo Biosciences Q2 2025 Earnings: Negative Earnings, Mixed Market Reactions - AInvest
Artelo Biosciences Inc. Building a Base Near SupportWeekly Profit Report & Fast Gain Swing Trade Alerts - sundaytimes.kr
Artelo Biosciences Reports Increased Losses Amid Strategic Investments - TipRanks
Artelo Biosciences reports Q2 EPS ($5.61) vs. ($4.52) last year - TipRanks
Artelo Biosciences Q2 Earnings: $5.61 EPS, FABP5 Inhibitor Pipeline Advances - AInvest
Artelo Biosciences Provides Business Update and Reports Second Q - GuruFocus
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results - MarketScreener
Artelo Biosciences Nears Major Clinical Readouts as Cash Position Strengthens to $13M - Stock Titan
Is It Too Early to Call Recovery in Artelo Biosciences Inc.July 2025 Fed Impact & AI Powered Market Entry Ideas - 선데이타임즈
Artelo Biosciences Receives Patent Protection Extension in Europe - mg Magazine
How to interpret RSI for Artelo Biosciences Inc. stockFree Portfolio Diversification Stock Ideas - Newser
Chart based exit strategy for Artelo Biosciences Inc.Free Optimized Watchlist With Daily Adjustments - Newser
Will Artelo Biosciences Inc. rebound enough to break evenBuy and Hold Return Summary with Charts - Newser
Artelo Biosciences Secures European Patent for ART27.13 Commercial Formulation, Extending Protection Through 2041 - AInvest
Risk vs reward if holding onto Artelo Biosciences Inc.ROI Focused Setup With Drawdown Analysis - Newser
Artelo Biosciences Surges 19.4% on Landmark Patent Approval for Cancer Anorexia Drug ART27.13 - AInvest
Artelo Biosciences secures European patent protection for cancer drug By Investing.com - Investing.com Nigeria
Artelo Biosciences secures European patent protection for cancer drug - Investing.com
Artelo Biosciences Receives Notice of Allowance from - GlobeNewswire
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 - MarketScreener
European Patent Win Secures 20-Year Protection for Revolutionary Cancer Anorexia Treatment in Phase 2 Trials - Stock Titan
Technical signs of recovery in Artelo Biosciences Inc.Free Value Investing Picks With Stability - Newser
What institutional flow reveals about Artelo Biosciences Inc.Breakout Watcher with Entry and Exit Alerts - Newser
Using Bollinger Bands to evaluate Artelo Biosciences Inc.Intraday Signal Forecast for Fast Traders - Newser
Multi factor analysis applied to Artelo Biosciences Inc.Swing Trade Watchlist with Entry Zones - Newser
Does Artelo Biosciences Inc. qualify in momentum factor screeningTrading Volume Anomaly Summary and Insight - Newser
Solana News Today: Solana Climbs 4.05% as Artelo Biosciences Invests $9.475M in Treasury - AInvest
Combining price and volume data for Artelo Biosciences Inc.Forecast Model for Intraday Buy Signals - Newser
Artelo Biosciences Partners with ABK Labs for Strategic Growth - The Globe and Mail
Artelo Biosciences (ARTL) down more than 70% since Jul 11 - AInvest
Artelo Biosciences Inc. Moves Into Bullish Territory Based on MACDEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Will a bounce in Artelo Biosciences Inc. offer an exitTrade Ideas Based on Fundamental Metrics - Newser
Artelo Biosciences Closes $9.475 Million Private Placement to Adopt Solana as Core Reserve Asset - AInvest
Artelo Biosciences (ARTL) down more than 50% since Jul 10 - AInvest
Artelo Biosciences Sees 15min Chart Trigger KDJ Golden Cross, Bullish Marubozu - AInvest
Analyst Maintains Buy Rating on ARTL with Target Price of $18 | - GuruFocus
Artelo Biosciences: Boral Capital maintains Buy, PT raised to $18 from $15. - AInvest
Biocardia Stock Plunges 12.76% Amid Market Volatility - AInvest
Artelo Biosciences stock soars after announcing $9.5M private placement for Solana-based treasury - Investing.com Canada
Artelo Biosciences (ARTL): D. Boral Capital Adjusts Price Target, Maintains Buy Rating | ARTL Stock News - GuruFocus
Artelo Biosciences stock rating reaffirmed at Buy by D. Boral Capital - Investing.com India
Solana News Today: Artelo Biosciences Allocates $9.475M to Build Solana Digital Asset Reserve Strategy - AInvest
Artelo Biosciences announces private placement to initiate Solana treasury - TipRanks
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):